By Cecilia Butini

The E.U. Medicines Agency hasn't yet reached a conclusion on a link between AstraZeneca PLC's Covid-19 shot and a rare blood clotting condition, an agency spokeswoman told the Wall Street Journal on Tuesday, adding that a review from the agency's Pharmacovigilance Risk Assessment Committee is still underway.

The European regulator responded to a comment request after Marco Cavaleri, who is the head of EMA's vaccines strategy, told Italian daily Il Messaggero that a link between AstraZeneca's shot and the disease was clear, although the agency hadn't yet finished its review.

The EMA spokeswoman said the agency would hold a press briefing on the matter as soon as its review gets finalized, which is expected to happen on Wednesday or Thursday.

AstraZeneca told The Wall Street Journal that it would decline to comment on Mr. Cavaleri's position.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

April 06, 2021 10:02 ET (14:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Astrazeneca Charts.